SLC5A2 and type 2 diabetes mellitus: Notably, recent cardiovascular outcome trials (CVOTs) assessing SGLT2 inhibitors have shown improvements in cardiovascular and renal outcomes in patients with and without type 2 diabetes mellitus (T2DM) [6,7,8,9,10,11,12].